Bausch Health · conference-presentation
Bausch Health Companies | Results Presentation Deck | 86 slides
86 pages · 0 arc beats · 2 loops
Bausch Health Companies | Results Presentation Deck | 86 slides
Bausch Health · 2022-02 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
151015202530354045505560657075808586
Deck intelligence map
1 coverage by narrative range · generated from this deck JSON
Narrative range 86 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Whole deck 86 slides 100% 86/86 slides 100% 86/86 slides · 372 hits — 0/86 slides
45.3% 39/86 slides · 40 hits 8.1% 7/86 slides — 0/86 slides
31.4% 27/86 slides Slide inventory
86 every slide · same image gating as the playbook
06
The slide uses a checklist format to distinguish between completed actions (checked) and future actions (unchecked).plan_implementation
Open slide detailLoop · Cost Of Inaction
07
The slide uses a split layout: blue boxes for specific leverage targets and a list for cash generation sources.present_solution
Open slide detailLoop · Cost Of Inaction
09
Includes a donut chart showing revenue breakdown by segment and a list of operational highlights.summarize
Open slide detailLoop · Cost Of Inaction
10
The table uses a hierarchical structure to group segments under Bausch + Lomb and Bausch Pharma, with a final total for Bausch Health.analyze_data
Open slide detailLoop · Quick Win Big Bet
11
Includes detailed footnotes regarding non-GAAP adjustments and organic growth calculations.analyze_data
Open slide detailLoop · Quick Win Big Bet
12
Includes both GAAP and non-GAAP financial measures.analyze_data
Open slide detailLoop · Quick Win Big Bet
13
The slide explicitly notes it is a supplement to Slide 10 with additional GAAP measures.analyze_data
Open slide detailLoop · Quick Win Big Bet
14
Includes a disclaimer box at the top right and detailed footnotes at the bottom.analyze_data
Open slide detailLoop · Quick Win Big Bet
15
Includes a callout box highlighting GAAP vs non-GAAP operating cash flow figures.analyze_data
Open slide detailLoop · Quick Win Big Bet
16
Includes detailed footnotes regarding debt adjustments and divestiture impacts.analyze_data
Open slide detailLoop · Quick Win Big Bet
17
The slide provides a breakdown of secured and unsecured debt maturities from 2022 to 2031.analyze_data
Open slide detailLoop · Quick Win Big Bet
19
Uses a waterfall-bridge framework to explain the variance between 2021 actuals and 2022 guidance.analyze_data
Open slide detailLoop · Quick Win Big Bet
20
Includes extensive footnotes regarding non-GAAP measures and specific expense exclusions.analyze_data
Open slide detailLoop · Quick Win Big Bet
22
Includes footnotes regarding non-GAAP measures and segment reporting.analyze_data
Open slide detailLoop · Quick Win Big Bet
23
The slide uses a winding path diagram to represent a business process or customer journey.present_solution
Open slide detailLoop · Quick Win Big Bet
24
Includes multiple chart types (bar, line, area) to demonstrate positive growth trajectories post-COVID-19.analyze_data
Open slide detailLoop · Quick Win Big Bet
25
Includes revenue growth metrics and segment-specific operational updates.analyze_data
Open slide detailLoop · Quick Win Big Bet
26
Includes footnotes regarding non-GAAP measures and data sources.summarize
Open slide detailLoop · Quick Win Big Bet
27
Uses a causal chain structure to link strategic actions to financial outcomes.summarize
Open slide detailLoop · Quick Win Big Bet
28
The slide uses bar charts to show growth across six metrics.analyze_data
Open slide detailLoop · Quick Win Big Bet
29
Includes geographic map visualization of top products by region and donut charts for revenue distribution.analyze_data
Open slide detailLoop · Quick Win Big Bet
30
Includes footnotes regarding non-GAAP measures and definitions.analyze_data
Open slide detailLoop · Quick Win Big Bet
31
The slide uses a three-column layout to present business-specific highlights.summarize
Open slide detailLoop · Quick Win Big Bet
32
The slide uses a checklist format to distinguish between completed actions (checked) and future actions (unchecked).plan_implementation
34
The slide illustrates a corporate restructuring where Bausch + Lomb and Solta Medical are separated from Bausch Pharma.compare_peers
35
The slide provides a status update on 14 distinct product development or launch initiatives.summarize
36
The slide lists specific clinical trial milestones and product launch timelines for three distinct business units.summarize
37
The slide uses a matrix-style timeline layout to track clinical trial progress across four distinct drug programs.plan_implementation
38
LOE = Loss of Exclusivity. Data shows significant revenue and profit declines for Bausch & Lomb and SALIX, partially offset by other units.analyze_data
39
LOE stands for Loss of Exclusivity. The table shows the financial impact of products losing patent protection.analyze_data
41
The table compares inventory levels across two distinct periods (2019-2020 and 2020-2021).analyze_data
42
Includes both GAAP and non-GAAP measures; highlights organic and reported revenue growth.analyze_data
44
Includes non-GAAP reconciliations and segment-specific performance indicators.analyze_data
46
Includes a specific callout for a 16% revenue increase in specific products.analyze_data
47
Includes specific disclosures regarding non-GAAP measures and corporate allocation exclusions.analyze_data
48
Includes both GAAP and non-GAAP measures with footnotes regarding constant currency and organic growth definitions.analyze_data
51
Includes specific segment revenue, gross profit, operating expenses, and profit margins with year-over-year variance analysis.analyze_data
52
The slide appears to be a template or a placeholder for financial data, as the table body is obscured or empty.analyze_data
53
The table includes footnotes regarding non-GAAP measures and constant currency calculations.analyze_data
54
The table highlights key product revenue trends for FY21, 4Q21, 3Q21, 2Q21, 1Q21, FY20, and 4Q20.analyze_data
55
The table provides a detailed breakdown of revenue in millions for each product, allowing for year-over-year and quarter-over-quarter comparison.analyze_data
56
The table provides a comparative view of product revenue, highlighting Xifaxan as the primary revenue driver.analyze_data
57
The table includes 8 columns of financial data for 10 products, totaling 80 distinct data points.analyze_data
58
The table highlights FY21 and FY20 columns with a blue background for emphasis.analyze_data
59
The table tracks revenue in millions for 10 specific products across 7 time periods.analyze_data
60
Includes both GAAP and non-GAAP measures; explicitly notes exclusion of corporate G&A and R&D allocation.analyze_data
61
Includes both GAAP and non-GAAP measures; explicitly notes exclusion of corporate G&A and R&D allocation.analyze_data
62
Includes both GAAP and non-GAAP measures with footnotes regarding reconciliation.analyze_data
67
The slide provides a detailed breakdown of adjustments to net income and their corresponding EPS impact.analyze_data
68
The slide presents two separate tables for Q4 2021 and Q4 2020, detailing line-item adjustments.analyze_data
69
The slide contains two distinct tables for 2021 and 2020 YTD performance.analyze_data
70
The table provides a bridge between GAAP and non-GAAP financial metrics by adding back amortization and asset impairments.analyze_data
71
The table provides a detailed breakdown of adjustments including amortization of intangible assets, asset impairments, and acquisition-related costs.analyze_data
72
The table provides quarterly data for 2021 and Q4 2020, alongside annual YTD data for 2018-2021.analyze_data
73
The table provides a detailed breakdown of adjustments including amortization of intangible assets and asset impairments.analyze_data
74
The table provides a bridge between GAAP and non-GAAP financial metrics by adding back amortization of intangible assets and asset impairments.analyze_data
75
The table provides a detailed breakdown of various financial adjustments including impairments, restructuring costs, and share-based compensation.analyze_data
76
The table includes adjustments for foreign exchange, divestitures, and discontinuations to arrive at organic revenue figures.analyze_data
77
Includes adjustments for exchange rates, divestitures, and discontinuations.analyze_data
78
Includes footnotes regarding non-GAAP measures, organic growth definitions, and currency exchange rate impacts.analyze_data
80
The table provides a detailed breakdown of adjustments including impairments, restructuring, and other non-GAAP items.analyze_data